Bank Of Nova Scotia Vir Biotechnology, Inc. Transaction History

Bank Of Nova Scotia

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$19.96 - $28.22 $452,752 - $640,114	-22,683 Reduced 69.4%	10,000 $253,000
Q3 2022 Nov 10, 2022	BUY	$18.26 - $31.1 $57,208 - $97,436	3,133 Added 10.6%	32,683 $630,000
Q2 2022 Aug 08, 2022	BUY	$19.08 - $26.7 $563,814 - $788,985	29,550 New	29,550 $753,000
Q2 2022 Aug 05, 2022	SELL	$19.08 - $26.7 $464,807 - $650,438	-24,361 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$21.19 - $40.01 $210,628 - $397,699	-9,940 Reduced 28.98%	24,361 $627,000
Q4 2021 Feb 11, 2022	BUY	$30.97 - $54.03 $768,303 - $1.34 Million	24,808 Added 261.33%	34,301 $1.51 Million
Q3 2021 Nov 12, 2021	SELL	$34.9 - $54.54 $41,077 - $64,193	-1,177 Reduced 11.03%	9,493 $413,000
Q2 2021 Aug 12, 2021	BUY	$38.75 - $51.0 $413,462 - $544,170	10,670 New	10,670 $504,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.